Authors: S Wolfsberger J Wunderer I Zachenhofer T Czech HG BöcherSchwarz J Hainfellner E Knosp
Publish Date: 2004/06/14
Volume: 146, Issue: 8, Pages: 831-839
Abstract
Pituitary adenomas represent an inhomogenous tumor entity in terms of growth rate invasiveness and recurrence To improve understanding of their different biological behaviour tumor cell proliferation markers are applied The aim of this study was to assess proliferation rates overall and in clinicopathological subgroups using MIB1 and the recently introduced cell proliferation marker antitopoisomeraseIIα TopoIIα Further we correlated the two markers and defined the clinical value of TopoIIα in pituitary adenomas as compared to MIB1We analyzed tumor cell proliferation rates using MIB1 and TopoIIα antibodies on samples of 260 primary pituitary adenomas We excluded recurrent cases and cases with drug pretreatment Median patient age at the time of surgery was 47 years range 14–86 years the malefemale ratio was 11 The total cohort comprised 110 nonfunctioning and 150 functioning cases Subtyping was performed according to hormonal expression as defined by WHO Tumor size and invasiveness were noted from surgical and/or radio logical reports in 95 of casesOverall MIB1 index was median 18 range 02–236 TopoIIα index was median 10 range 0–144 with a strong correlation between the two markers R=0837 P0001 As compared to MIB1 mean TopoIIα values were significantly lower by a factor 18 Only MIB1 was significantly higher in invasive as compared to noninvasive adenomas in tumors ≤3 cm in diameter and in the agegroup 21–40 Female gender had significantly higher MIB1 and TopoIIα indices than male Silent ACTHcell and PRLproducing adenomas had the highest nullcell adenomas and gonadotropinomas the lowest proliferation values respectivelyOur data show a strong correlation between MIB1 and TopoIIα indices in pituitary adenomas Only MIB1 but not TopoIIα demonstrated significantly higher values in invasive adenomas Therefore MIB1 seems more useful than TopoIIα for decisions regarding postoperative patient management
Keywords: